- $525.25m
- $513.94m
- $0.04m
Brief: Entera Bio Announces Execution Of Key Regulatory Milestones For Eb613, The First Oral Anabolic Drug Proposed For The Treatment Of Osteoporosis Miranda Toledano Assumes CEO Position
Brief: Entera Bio Files Prospectus For Offering Of 5 Million Ordinary Shares
Brief: Entera Bio Ltd Files For Secondary Offering Of Up To 3.8 Million Ordinary Shares By Selling Securityholders
Brief: Entera Bio Ltd Files For Mixed Shelf Of Up To $100 Million
Brief: Entera Bio Board Member, Miranda Toledano, To Assume Role Of Chief Business Officer, Chief Financial Officer, And Head Of Corporate Strategy
Entera Bio Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Entera Bio Reports Q1 Loss Per Share Of $0.13
Entera Bio Ltd expected to post a loss of 18 cents a share - Earnings Preview
Brief: Entera Bio Files Patent Applications For Inventions That Optimize Its Platform Technology For Oral Delivery Of Large Molecule Therapeutics
Entera Bio Ltd reports results for the quarter ended in December - Earnings Summary
Brief: Entera Bio Announces Successful EB613 End-Of-Phase 2 Meeting With FDA: FDA Agrees To Phase 3 12-Month Study With Lumbar Spine BMD As Primary Endpoint
Brief: Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data For Oral PTH Formulation At Late Breaker ASBMR Conference Session
Brief: Entera Bio Selected To Present At ASBMR 2021 Annual Meeting
Entera Bio Ltd reports results for the quarter ended in June - Earnings Summary
Entera Bio Ltd expected to post a loss of 12 cents a share - Earnings Preview
Brief: RA Capital Management L.P. Reports 9.9% Passive Stake In Entera Bio Ltd
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:32 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:46 AM